Document Detail

Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients.
MedLine Citation:
PMID:  21415237     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: To compare the effects of oral capecitabine-containing chemotherapy regimens with i.v. 5-fluorouracil (5-FU)-containing chemotherapy regimens on overall survival in patients with gastrointestinal cancers.
METHODS: A meta-analysis, based on individual patient data from six randomised non-inferiority trials, was carried out at the request of regulatory authorities to compare the effects of single-agent capecitabine or capecitabine-containing chemotherapy versus matched 5-FU-based regimens in terms of overall survival in patients with stage III colon, metastatic colorectal or advanced gastric cancer.
RESULTS: Data from a total of 6171 patients with stage III colon cancer (n = 1987), metastatic colorectal cancer (n = 3868) or advanced gastric cancer (n = 316) were included. A total of 3097 patients were treated with capecitabine-containing chemotherapy and 3074 patients with 5-FU-containing chemotherapy. The unadjusted hazard ratio for overall survival for capecitabine-containing chemotherapy versus 5-FU-containing chemotherapy was 0.94 (95% confidence interval 0.89-1.00; P = 0.0489).
CONCLUSIONS: Oral capecitabine is at least equivalent to i.v. 5-FU in terms of overall survival in patients with gastrointestinal cancers. Capecitabine and 5-FU can be used interchangeably in these patient populations.
J Cassidy; L Saltz; C Twelves; E Van Cutsem; P Hoff; Y Kang; J P Saini; F Gilberg; D Cunningham
Related Documents :
21147867 - Corticosteroid use in patients with glioblastoma at first or second relapse treated wit...
3756767 - Treatment of metastatic adrenal cortical carcinoma with cisplatin and etoposide (vp-16).
21487387 - What can molecular pathology contribute to the management of renal cell carcinoma?
21153827 - Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients t...
10360607 - Phase ii trial of docetaxel with dexamethasone premedication in patients with advanced ...
22015047 - Clinico-pathological and biological prognostic variables in squamous cell carcinoma of ...
Publication Detail:
Type:  Comparative Study; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't     Date:  2011-03-17
Journal Detail:
Title:  Annals of oncology : official journal of the European Society for Medical Oncology / ESMO     Volume:  22     ISSN:  1569-8041     ISO Abbreviation:  Ann. Oncol.     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-11-22     Completed Date:  2012-03-16     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  9007735     Medline TA:  Ann Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  2604-9     Citation Subset:  IM    
Glasgow University, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / therapeutic use*
Colorectal Neoplasms / drug therapy*,  mortality
Deoxycytidine / analogs & derivatives*,  therapeutic use
Fluorouracil / analogs & derivatives*,  therapeutic use*
Kaplan-Meier Estimate
Multivariate Analysis
Randomized Controlled Trials as Topic
Stomach Neoplasms / drug therapy*,  mortality
Treatment Outcome
Reg. No./Substance:
0/Antineoplastic Agents; 51-21-8/Fluorouracil; 6804DJ8Z9U/capecitabine; 951-77-9/Deoxycytidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Metabolic syndrome and the risk of breast cancer in postmenopausal women.
Next Document:  Expert second-opinion pathology review of lymphoma in the era of the World Health Organization class...